SEHK:1093Pharmaceuticals
CSPC Pharmaceutical Group (SEHK:1093) Expands AstraZeneca Ties, Is The Upside Already Priced In?
CSPC Pharmaceutical Group (SEHK:1093) is back in focus after a new collaboration, option and license agreement with AstraZeneca to develop siRNA based renal disease treatments using CSPC’s AI enabled nucleic acid drug platforms.
See our latest analysis for CSPC Pharmaceutical Group.
Those R&D updates and the AstraZeneca collaboration come as CSPC Pharmaceutical Group’s share price has climbed 15.10% over the past week, yet remains down 15.24% over three months. The 3 year total shareholder...